Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12855648 | 0.81 | CA2 (0.36) | CA2POLBGAAMAPK1NPSR1 | |
| SCHEMBL12855649 | 0.81 | CA2 (0.36) | CA2POLBGAAMAPK1NPSR1 | |
| SCHEMBL328617 | 0.79 | CA2 (0.35) | CA2 | |
| SCHEMBL12855647 | 0.79 | CA2 (0.35) | CA2 | |
| SCHEMBL10821377 | 0.79 | CA2 (0.39) | CA2POLBGAAMAPK1NPSR1 | |
| SCHEMBL22778888 | 0.77 | CA2 (0.32) | CA2 | |
| SCHEMBL19479799 | 0.77 | POLB (0.33) | CA2POLBGAAMAPK1NPSR1 | |
| SCHEMBL988652 | 0.77 | POLB (0.33) | CA2POLBGAAMAPK1NPSR1 | |
| SCHEMBL19479801 | 0.77 | POLB (0.33) | CA2POLBGAAMAPK1NPSR1 | |
| SCHEMBL12855572 | 0.77 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865212-B2 | Intermediate for preparing eribulin mesylate and process for preparing the same | YONSUNG FINE CHEMICAL CO.. LTD. (KR) | 2020-12-15 | — | — | US | disclosed |
| US-20190337964-A1 | INTERMEDIATE FOR PREPARING ERIBULIN MESYLATE AND PROCESS FOR PREPARING THE SAME | YONSUNG FINE CHEMICAL CO., LTD. (KR) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337964-A1 | INTERMEDIATE FOR PREPARING ERIBULIN MESYLATE AND PROCESS FOR PREPARING THE SAME | ERLIN1, DHPS, ERLIN2 | CA2 4239/4885OGA 2509/4885POLB 2337/4885 |
| US-10865212-B2 | Intermediate for preparing eribulin mesylate and process for preparing the same | ERLIN1, DHPS, ERLIN2 | CA2 4239/4885OGA 2509/4885POLB 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.